Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Exclusion Criteria

• - History of any clinically important disease or disorder.
• - Receipt of any immunoglobulin (either COVID-19 or non-COVID related) or blood products within 6 months prior to Day 1.
• - Receipt of an EVUSHELD monoclonal antibody (mAb) against SARS-CoV-2 within last 15 months before Day 1.
• - Receipt of a COVID-19 vaccine within 14 days prior to Visit 1.
• - SARS-CoV-2 infection within one month prior to Visit 1 (confirmed either by laboratory testing or a rapid test [including at-home testing]).
• - Women who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration.
• - Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy,
• - Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. This includes any acute (time-limited) or febrile (temperature ≥ 38.0°C [100.4ºF]) illness/infection on day prior to or day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the Screening Period or may be rescreened once.
• - Any abnormal laboratory values as described in protocol.
• - Any known HIV or hepatitis B or C infection at Screening.
• - History of alcohol or substance abuse that in the opinion of the Investigator might interfere with the trial conduct or completion.
• - Known hypersensitivity to AZD3152.
• - Previous hypersensitivity or severe adverse reaction following administration of a mAb.